LRRK2 and Parkinson disease: Among these, genetic variants with well-established clinical utility, particularly Alzheimer's disease-linked mutations in APP, PSEN1, and PSEN2, as well as LRRK2 and GBA mutations in Parkinson's disease, show the strongest translational potential because they are already used in genetic risk stratification and counseling [84,85].